星湖科技(600866.SH):1-9月利巴韋林原料藥的營收佔比低於1%
格隆匯12月29日丨星湖科技(600866.SH)公佈股票交易異常波動公吿,公司股票於2021年12月27日、28日、29日連續3個交易日內收盤價格漲幅偏離值累計超過29.28%,短期漲幅較大,敬請投資者注意二級市場交易風險。
公司主要從事食品添加劑、化學原料藥及醫藥中間體、飼料添加劑的研發、生產和銷售,是為食品加工、醫藥製造、飼料加工等相關企業提供生產原料。
目前,公司主營業務和產品結構均未發生重大變化。利巴韋林原料藥為公司的產品之一,屬於下游製藥企業的原材料,其產品的最終用途由下游企業來安排,2021年1-9月利巴韋林原料藥的營業收入約為467萬元,佔公司總營業收入低於1%,佔公司營業收入比例極小,對公司整體經營業績影響較小。
經公司自查並向公司控股股東核實,截至公吿披露日,除公司已披露事項外,不存在應披露而未披露的重大信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.